Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) viral spike protein-angiotensin converting enzyme-2 (ACE2) interaction-Reference-Cited by-同舟云学术

Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) viral spike protein-angiotensin converting enzyme-2 (ACE2) interaction

Published:2020-08 Issue: Volume:178 Page:114123
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Williamson Gary^ORCID,Kerimi Asimina

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference20 articles.

1. SARS-CoV-2 entry genes are most highly expressed in nasal goblet and ciliated cells within human airways;Sungnak;Quant. Biol.,2020

2. M.S. Smith, J.C., Repurposing therapeutics for COVID-19: Supercomputer-based docking to the SARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ACE2 Interface, ChemRxiv http://doi.org/10.26434/chemrxiv.11871402.v4 (2020).

3. Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells;Yi;J. Virol.,2004

4. Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris;Nguyen;Biotechnol. Lett.,2012

5. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?;Sargiacomo;Aging,2020

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The flavonoid quercetin decreases ACE2 and TMPRSS2 expression but not SARS‐CoV‐2 infection in cultured human lung cells;BioFactors;2024-06-17

2. Effect and mechanism of quercetin or quercetin‐containing formulas against COVID‐19: From bench to bedside;Phytotherapy Research;2024-03-13

3. Quercetin may reduce the risk of developing the symptoms of COVID-19;AVICENNA J PHYTOMEDI;2024

4. Flavonoids derived from medicinal plants as a COVID‐19 treatment;Phytotherapy Research;2024-01-29

5. Inhibiting SARS-CoV-2 viral entry by targeting spike:ACE2 interaction with O-modified quercetin derivatives;RSC Medicinal Chemistry;2024